Boston Scientific seeks closure
This article was originally published in The Gray Sheet
Executive Summary
Company becomes exclusive worldwide distributor of Therus' vascular closure products and will make an equity investment with a future option to buy the Seattle company under a May 2 agreement. A feasibility study of Therus' HIFU (high intensity focused ultrasound) technology to close femoral puncture wounds was recently completed, and the firm expects to have a product in Europe in 2003 and in the U.S. by 2004. On April 23, Boston Scientific announced a licensing and equity agreement with SUB-Q for its QuickSeal vascular sealing device (1"The Gray Sheet" April 29, 2002, p. 19). Separately, Boston Scientific announces April 30 that it will take over distribution rights for Onux Medical's Touche tissue fixation suturing products and will help Onux develop technology to treat peptic ulcer disease...
You may also be interested in...
Boston Scientific Sees $100 Mil. Potential In BEI Medical’s ThermAblator
Boston Scientific will expand its women's health promotional reach to include gynecologists, in hopes of developing the menorrhagia market following the $95 mil. acquisition of BEI Medical's ablation technology
SUB-Q QuickSeal Closes Hole In Boston Scientific Endovascular Line
Boston Scientific will enter the rapidly expanding vascular access closure device market in May through the distribution of SUB-Q's QuickSeal vascular sealing device, under a licensing and equity agreement announced April 23. The QuickSeal earned PMA approval on March 25
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.